Apr. 2 at 10:18 PM
$AEON
1) Milestone Expected Timing Impact.
AAN Presentation April 18–22, 2026 Scientific validation; could attract a partner.
2) BPD Type 2b FDA Meeting Late 2026.
The "green light" to start the final phase of development.
3) Completion of Comparability End of 2026. Proves the drug is effectively a carbon copy of Botox.
4) Potential BLA Filing 2027.
The formal application for FDA approval to sell the drug.
Above courtesy of "Gemini".
They only have funds that will get them through the end of the 3rd quarter of this year, which means AEON will either partner with someone, seek alternative funding, or maybe be bought out. Worst case scenario would be offering/selling more shares leading to dilution.
I believe their operating costs are in the negative as well. However, intrinsic value and future potential would balance that out.
I'm definitely not any type of financial expert.
Good luck and all the best to whatever you decide.
